T. Rowe Price Associates’s MBX Biosciences MBX Stock Holding History

T. Rowe Price Associates’s Portfolio MBX Stock Details MBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$30.7M	Buy	1,029,007 +188,501	+22%	+$6.41M	﹤0.01%	924
2025 Q4	$26.5M	Sell	840,506 -114,220	-12%	-$2.77M	﹤0.01%	995
2025 Q3	$16.7M	Sell	954,726 -392,184	-29%	-$5.24M	﹤0.01%	1095
2025 Q2	$15.4M	Buy	1,346,910 +245,994	+22%	+$2.51M	﹤0.01%	1016
2025 Q1	$8.13M	Sell	1,100,916 -60,611	-5%	-$641K	﹤0.01%	1149
2024 Q4	$21.4M	Sell	1,161,527 -31,411	-3%	-$669K	﹤0.01%	982
2024 Q3	$31M	Buy	+1,192,938	New	+$27.3M	﹤0.01%	882

Other funds holding MBX

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

T. Rowe Price Associates's MBX Position: Q1 2026 in Review

T. Rowe Price Associates increased its MBX Biosciences (MBX) stake by 22% in Q1 2026, buying an estimated $6.41M and bringing the position to 1,029,007 shares worth $30.7M. The position accounts for ﹤0.01% of the portfolio, ranked #924.

T. Rowe Price Associates first reported a position in MBX in Q3 2024 and has held it in 7 quarters since. The position peaked at $31M in Q3 2024. 157 funds tracked by Wall St. Rank hold MBX as of Q1 2026.

T. Rowe Price Associates held 1,029,007 shares of MBX Biosciences worth $30.7M as of Q1 2026.
T. Rowe Price Associates bought 188,501 MBX Biosciences shares in Q1 2026, an estimated $6.41M.
MBX Biosciences made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #924 holding.
T. Rowe Price Associates first reported a position in MBX Biosciences in Q3 2024 and has held it in 7 quarters since.
T. Rowe Price Associates's MBX Biosciences position peaked at $31M in Q3 2024.
157 funds tracked by Wall St. Rank held MBX Biosciences as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.